Mass General: Investigational ALS Drug Generates Promising Clinical Trial Results
September 03, 2020
September 03, 2020
BOSTON, Massachusetts, Sept. 3 -- Massachusetts General Hospital issued the following news release:
An experimental medication slows the progression of the neurodegenerative disease called amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to recently released results from a clinical trial run by investigators at the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) and Amylyx Pharmaceuticals, Inc., the company that manufacture . . .
An experimental medication slows the progression of the neurodegenerative disease called amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, according to recently released results from a clinical trial run by investigators at the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) and Amylyx Pharmaceuticals, Inc., the company that manufacture . . .